THERAPEUTIC POTENTIAL OF BIODEGRADABLE MESELMINE MICROSPHERES IN THE TREATMENT OF ULCERATIVE COLITIS

NM MAHAJAN*, 1, DR DM SAKARKAR2, AS MANMODE3

1Assistant Professor, SGSPS Institute of Pharmacy, Akola (M. S.)
2Principal, Sudhakarrao Naik Institute of Pharmacy, Pusad, Dist- Yavatmal(M.S.) and Dean, Faculty of Medicine, Sant Gadge Baba Amravati University, Amravati (M.S.)
3Research Scientist, Astron Research Limited, Ahmadabad, Gujarat, India.
E-mail: nm.mahajan78@gmail.com

ABSTRACT
The use of microparticles (MPs) for targeted oral drug delivery to the inflamed gut tissue in inflammatory bowel disease was examined. Such a strategy of local drug delivery would be a distinct improvement compared with existing colon delivery devices for the ulcerative colitis. An experimental colitis was induced by acetic acid to Wistar rats. Meselamine, a front line drug in the treatment of ulcerative colitis, was incorporated within poly (lactic-co-glycolic acid) i.e. PLGA microspheres, which were administered once a day orally and rectally for five consecutive days. A clinical activity score, colon body weight ratio, myeloperoxidase activity and ulcer index were determined to assess the inflammation. All micro particulate formulations proved to be as efficient as compared to the drug in suspension in mitigating the experimental colitis. The clinical activity score, colon body weight ratio, myeloperoxidase activity and ulcer index decreased significantly (p<0.05), after the oral administration of meselamine microspheres suspension. The free drug, meselamine, suspension does not found effective in terms of clinical activity, myeloperoxidase activity and ulcer index, as is evident from the non significant decrease in clinical parameters. The meselamine microspheres further proved their potential in reducing the inflammation proved by the histopathology of the resected colon from every group of animals. This new delivery system enabled the drug to accumulate in the inflamed tissue with higher efficiency than when given as suspension of drug. The microspheres deposition in the inflamed tissue should be given particular consideration in the design of new carrier systems for the treatment of inflammatory bowel disease.

Key words: Microspheres, Ulcerative colitis, PLGA, Meselamine, Clinical activity.

INTRODUCTION
The ordinary treatment of inflammatory bowel disease requires the frequent intake of anti-inflammatory drugs at high doses, which causes the absorption of those drugs from the small intestine, leading to significant adverse events. Therefore, several strategies have been followed such as the development of prodrugs that deliver drugs specifically in the large bowel after cleaving the active part from the hydrophilic carrier by specific bacterial enzymes in the colon1 and the development of solid dosage forms that release the drug in the colon in dependence of the physiological environment2. The administration of drugs by rectal route is also currently used. However, it is not effective when the inflamed tissues are located in the upper parts of the colon.

Although prodrugs lead to reduced adverse effects, a more comfortable dosage frequency cannot be achieved. Sustained drug release devices, e.g., pellets, capsules, or tablets, delivering the drug specifically in the colon for a longer time period have been developed. However, their efficiencies seem to be decreased in many cases due to the diarrhea, a symptom of inflammatory bowel disease that enhances the elimination and reduces the possible drug release time3. Thus, a carrier system that delivers the drug specifically and exclusively to the inflamed regions after oral administration for a prolonged period would be desirable. Such a system could reduce side effects significantly in the case of conventional chemical anti-inflammatory compounds.

Because microspheres can be designed to control drug release after oral administration, the development of such microspheres seems to be promising primarily to reduce the dosage frequency. In the case of colitis, a strong cellular immune response is known from the inflamed regions, i.e., in general, an increased presence of neutrophils, natural killer cells, mast cells, and regulatory T cells, which have an important role in the pathophysiology of inflammatory bowel disease4.

Moreover, it has been reported that microspheres and nanoparticles can be efficiently taken up by macrophages5. Thus, it may be expected that particle uptake into those immune-related cells or the disruption of the intestinal barrier function could allow the accumulation of the particulate carrier system in the desired area6. A subsequent increase of residence time that would be postulated for microparticles and nanoparticles compared with existing drug delivery systems allow a dose reduction. Indeed, it has been demonstrated that microparticles containing dexamethasone showed previously promising results in colitis-induced mice7. In addition, the successful oral administration of drugs with strong adverse effects pertaining to the high doses such as meselamine and rolipram may be a new medical approach.

The aim of this project is to test in vivo targeting potential of microspheres to the inflamed tissue. The suitability of microspheres for targeted drug delivery to the inflamed gut tissue in inflammatory bowel disease i.e. ulcerative colitis will be examined. This is an attempt to design and fabricate microspheres of salicylates like 5-aminosalicylic acid encapsulated in biodegradable polymers such as PLGA, which may shown slow release and are targeted to inflamed colon in ulcerative colitis is examined in experimental animal models. To compare the efficiency of the microspheres treatment, different groups of rats received suspension of both, free anti-inflammatory drug and microspheres. The mitigating effect of all formulations was determined by a clinical score system, the colon/body weight ratio, myeloperoxidase activity and ulcer index.

MATERIALS AND METHOD
The biodegradable polymer Poly (DL- lactide-co-glycolide) i.e. PLGA 50:50 (Molecular weight 10,000) was purchased from Boehringer Ingelheim, Germany. PVA (Polyvinyl alcohol) and Meselamine (5-aminosalicylic acid) was purchased from Hi-media, Mumbai. All other chemicals and reagents are of analytical grade purchased from Sigma Chemicals, Mumbai and Merck Chemicals, Mumbai. All animal experimental protocols are approved by Institutional Ethical Committee clearance bearing the number 817/04/AC/ICPSEA.

EXPERIMENTAL
Preparation of Biodegradable Microspheres
The preparation of microspheres was based on emulsification solvent evaporation method. Fix amounts of poly (lactic-co-glycolic acid) (125 mg) and meselamine (50 mg) were dissolved in the solvent blend consisting of 5ml methylene chloride, 5ml DM50, 10 ml acetone. This solution was slowly poured into 50 ml of 2% w/v polyvinyl alcohol and an oil/water-emulsion was formed by
Evaluation of Therapeutic Potential of Microspheres

Therapeutic potential of meselamine microspheres in the treatment of ulcerative colitis was determined by using experimentally induced ulcerative colitis model in rats. All animal experiments were carried out in accordance with the Recommendations in the Guide for Care and Use of Laboratory Animals. The study was conducted at Sudhakarrao Naik Institute of Pharmacy,浦线, Dist. - Yadavmal (M.S.) after obtaining Institutional Ethical Committee clearance bearing the number B/17/04/ac/CPCSEA.

Method of Inducing Experimental Colitis

The acetic acid induced colitis model was selected as well recognized experimental model that allows the induction of colitis at an exact location. A model of diffuse colitis in rats induced by intraluminal colonic instillation or serosal application of dilute acetic acid was described by MacPherson and Pfeiffer. Ritzpatrick et al. tested the anti-inflammatory effects of various drugs on acetic acid induced colitis in the rat.

Wistar rats of either sex aged 12-15 weeks and weighing about 230-250 gm were used for the study. All animals were housed in an air conditioned room at 22±3°C, 55±5% humidity, 12 hours light/dark cycle and allowed to free access to water and laboratory chow for the duration of study. To induce the model of inflammation in rat colon, the animals were arbitrarily separated into treatment group (n=6/group), fasted 24 hrs with free access to water and then lightly narcotized with ether. A soft polyethylene cannula fitted with adapter of 8cm length was used.

The open end of tube was sealed and running length was perforated at dist of 0.5cm at 90° apart from each other. This specially designed polyethylene catheter was then inserted rectally into colon such that the tip of catheter was 8cm proximal to anus. The 1ml of 10% acetic acid was then inserted rectally into colon such that the tip of catheter was 8cm proximal to anus. The 1ml of 0.9% saline was used for intravenous injection. The rats were sacrificed and abdomen was opened and the distal colon was rapidly excised and opened longitudinally along +5 mesenteric ridge. The fecal contents were removed and the colon was washed with 0.9% (w/v) saline and placed with mucosal surface upward over glass plate or slide chilled with ice. The ratio of 8cm segment distal colon weight was calculated as index of colonic tissue edema as described by Yue, et al.

Myeloperoxidase Activity (MPO Activity)

The measurement of Myloperoxidase activity is the first quantitative assessment to quantify the severity of colitis. It is reliable index of inflammation caused by infiltration of activated neutrophils to the inflamed tissue. Activity was analyzed by using std. method given by Krawisz, et.al. Briefly, distal colon specimen was minced in 1ml of HTAB buffer (0.5% in 50mM phosphate buffer) on ice and homogenized. The homogenate was sonicated for 10 sec. (MicrosonTM XL 2007, Ultrasonic Cell Disruptor, Microsonix Inc.,USA), freeze-thawed three times and centrifuged at 12,000 rpm for 3 min (Eppendorf AG 22331, Germany). Myeloperoxidase activity in the supernatant was measured spectrophotometrically. Supernatant (0.0 ml) was added to 0.167 mg/ml of o-dianisidine hydrochloride and 0.005% hydrogen peroxide, and the change in absorbance at 460 nm was measured. One unit of myeloperoxidase activity was defined as the amount that degraded 1µmol of peroxidase per minute at 25 °C. The results were expressed as U/mg tissue as given by Jagtap, et al.

Assessment of Macroscopic Ulceration (Ulcer Index)

Gross mucosal damage was scored on 0-3 grade scale by single observer blind to treatment as described by Rodrigue, et al. Damage was scored as follows: Score 0 represents no damage, score 1 localized hyperemia with slight or minimal ulceration, and score 2, linear ulcers and one or two regions with ulcer of 1-2 cm and score 3 for severe ulceration (regions with ulcers > 2cms). The macroscopic ulceration can also be determined by calculating the ulcer index of every group. The ulcer index was determined by opening the stomach on greater curvature and the scores were given 0 to 3 depending upon the severity of ulcers (normal colored colon = 0, red colon = 0.5, ulcer score 1 = 1, 5% of mucosa < > 2 cm and ulcer score 2 = 2 cm and s core 3 = 3). Ulcer index (UI) was then calculated from the above scorings as follows:

\[ UI = U_1 + U_2 + U_3 \times 10^{-1} \]

Where \( U_1 \) is the average number of ulcers per animal, \( U_2 \) is the mean severity of ulcer score and \( U_3 \) is the percentage of animals with ulcer incidence.

Histological Evaluation

After scoring, two representative tissue samples were excised from each colon and maintained in 10% (v/v) formaldehyde for the microscopic studies. When visible ulceration or inflammation was present, at least one of the samples from affected region was taken.
Figure 1: Clinical activity score during treatment. (n = 6) [MP control (Group C) being similar to the colitis control (Group B) Group D and Group F shows significant, $P<0.01^{**}$, decrease in clinical activity compared with colitis control rats given saline] Error bars are not shown for clarity reasons.

Figure 2: Colon body weight ratio after treatment [Each bar is an average value ± S.D. of six animals of each group. MP orally treated group (Group D) shows significant lowering, $p < 0.05^*$, of colon/body weight ratio than the average value of the control group (Group B)].

Figure 3: Myeloperoxidase activity after treatment [Each bar is an average value ± S.D. of six animals of each group. MP orally treated group (Group D) and rectally treated (Group F) shows significant lowering, $p < 0.01^{**}$, of MPO activity than the average value of the control group (Group B)].

Figure 4: Ulcer Index after treatment [Each bar is an average value ± S.D. of six animals of each group. MP treated group (Group D) orally and rectally (Group F) shows significant lowering, $p < 0.01^{**}$, ulcer index than the average value of the control group].

Figure 5: Histopathological slide of normal control group (Group A).

Figure 6: Histopathological slide of colitis control group (Group B).
The samples were processed routinely and embedded in paraffin blocks. Sections of 5µm were stained with hematoxylin and eosin. Microscopic assessment was done and slides were interpreted.

**Statistical Analysis**

The mean value ± standard deviation (S.D.) was calculated for each parameter. Results were statistically analyzed by descriptive statistical methods (ANOVA and Dunnet's Multiple Comparison Test). $P < 0.01^{**}$ and $P < 0.005^*$ indicates statistical significance. MS Windows based Graph Pad Prism Software is used for statistical analysis.

**RESULT AND DISCUSSION**

The microspheres prepared with poly [DL-lactide-co-glycolide], a biocompatible and biodegradable polymer were characterized in terms of particle size, drug content, surface potential, encapsulation efficiency, and drug release (Table 1). Microspheres prepared by the emulsification solvent evaporation method had a spherical shape, submicrometer size, and were relatively monodispersed. Discrete spherical microspheres having a mean diameter of about 1.15µm to 1.5µm with low standard deviations (monodispersity) were produced. The small polydispersity index suggested that the size distribution of the products is fairly monomodal. The above-mentioned monodispersed size distribution and excellent redispersibility of microspheres indicate that the surface of PLGA microspheres is stabilized by some reasons to prevent aggregation. The most likely reason to explain the findings might be the adsorption of PVA to PLGA microparticles.

To evaluate the therapeutic value of meselamine-containing microspheres, the effect of the carrier system was studied on preexisting colitis. All animals received an intrarectal application of acetic acid except the healthy control group. Before this time point, animals showed no clinical problems. After inducing the experimental colitis the clinical score increased rapidly and consistently for the next 3 days for all groups (Fig. 1). The inflamed tissue showed an extremely increased mucus production in the area of distal colon compared with the histology of healthy gut sections from the control group. Significant damages of the intestinal tissue, e.g., ulceration, have been observed. Starting from day 4, rats received orally either meselamine suspension or meselamine microspheres suspension daily for five consecutive days, only the colitis control group received saline instead. The clinical activity score was used to evaluate the severity of the colonic inflammation and the colitis control group proved to be an excellent model of inflammation as evidenced by the highly increased clinical activity.
All drug-receiving groups showed a decrease of inflammation severity after a lag of 24 to 48 h. The difference between drug-treated groups and colitis controls became significant ($P < 0.05$) on day 8. During the whole mesalazine treatment period the clinical activity was lowered by free drug and by the two drug carrier formulations as well. After the 5 days without drug treatment, the free drug group does not show the significant reduction in the clinical activity, whereas for the microsphere groups continuously reduced clinical activity scores was observed.

On day 9 (24 h after the last drug administration), the first series of animals was sacrificed and colon/body weight ratio and myeloperoxidase activity were determined to quantify the inflammation. The drug-treated groups showed a distinct decrease in the colon/body weight ratio compared with the colitis control group (Fig. 2). The difference between free drug and the micro particles formulations was significant. Furthermore, the myeloperoxidase activity in samples obtained from the inflamed colonic tissue was examined (Fig. 3).

Here also, an enormous difference between mesalamine microspheres-treated group, MPO activity = 9.0 U/mg ($P < 0.05$) and colitis control groups (MPO activity = 34.75 U/mg) was found. As observed previously, significant differences for the mitigating effect of all mesalazine-receiving groups were observed. Whereas, the colitis control group, showed a continuously strong colonic inflammation reflected by a high clinical activity score.

The macroscopic changes include marked thickening of the intestinal wall associated with hemorrhages, epithelial exfoliation and ulcer that exceed 2 cm were seen. A narrowing of the lumen of the colon adjacent to the inflamed sites with a proximal dilatation of the bowel was also seen in the acetic acid-treated rats, but generally the colon was not perforated. As evident by the ulcer index (Fig. 4) which was calculated on the basis of scores correspond to the severity of ulcer, colitis control group having ulcer index, $U_c = 97.00$ which is quite high as compared to normal group having ulcer index value, $U_n = 46.40$. Microsphere treated group both orally and rectally having ulcer index values as $U_e = 482.90$ and $U_r = 486.50$, respectively which are significant ($P < 0.05$) as compared to the group receiving drug suspension having ulcer index value $U = 94.70$ which is just short of colitis control group.

Histopathological changes of the colon in case of inflammatory response included appearance of local hyperemia, and mild to severe inflammatory cellular infiltrate including polymorphonuclear leukocytes, eosinophils, lymphocytes and granulocytes can be observed. The inflammation was spread over the mucosa, submucosa, muscle layer and included serosa. Normal control group A, representative slide (Figure 5), showed normal colonic mucosa with regularly formed colonic folds covered by intact mucosa. Only occasional leukocytes are present in the lamina propria of the mucosa.

Histological examination of colon sections from control rats showed no signs of inflammation. The histopathological features of group B, colitis control group (Figure 6), indicates invagination of mononuclear cells, glands appears exhausted along with focal lymphocytic aggregation. Five days after induction of colitis the group C (Figure 7) administered with blank micro particles showed evidence of mucosal congestion, and hemorrhagic ulceration in mucosa and submucosa. In other word, it has the same histological features like the acetic acid treated group.

Treatment of rats with the mesalazine microspheres suspension receiving orally, Group D, significantly attenuated the extent and severity of the histological signs of cell damage (Figure 8). It has normal appearance and shows no sign of ulceration on seeding.

Histopathological studies confirmed the anti-inflammatory potential exerted by the microspheres on inflamed colonic tissues, as evident from the representative slide. Free drug mesalazine suspension treated group E (Figure 9), even after the daily dosing, there is still some signs of inflammatory response such as degree of edema, but no cross-mucosal damage.

Also note the difference in colon cross-sectional area, which is partially reversed by mesalazine. Histological characteristics of rectally treated drug loaded microspheres suspension group F (Figure 10) shows the inflammation of submucosa along with hyper active elongated glands. Because of accumulation of lymphocytes, histiocytes, and fewer neutrophils there is marked crypt destruction. The inflammatory process is limited to the mucosa and submucosa, severe colonic inflammation, characterized by a dense inflammatory cell infiltrate in all colonic wall structures and widespread mucosal sloughing. These inflammatory signs might be due to the frequent insertion of polyethylene catheter for the dosing that may cause the physical damage to the ulcers there by enhancing the inflammation process.

ACKNOWLEDGEMENT

We highly oblige the kind support for the physicochemical study by Astron Research Ltd., Ahmadabad (G.L.). We also acknowledge the support of Sudhakarrao Naik Institute of Pharmacy,浦沙, Dist. - Yavatmal (M.S.) for animal study in their laboratory having Institutional Animal Ethical Committee (Regd. No. 729/02/a/CPCSEA).

REFERENCES


---

### Table 1: Optimization Parameters of Microspheres

<table>
<thead>
<tr>
<th>Sample Number</th>
<th>Method of Preparation</th>
<th>Particle size (µm)</th>
<th>Polydispersity Index (PI)</th>
<th>Zeta Potential (mV)</th>
<th>Drug Content (%w/w)</th>
<th>%Drug Entrapment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample A</td>
<td>SEDS</td>
<td>1157 ± 1.9</td>
<td>0.166</td>
<td>-58.4 ± 1.4</td>
<td>1.7 (1.8; 1.9)</td>
<td>24.2 (23.6; 24.9)</td>
</tr>
<tr>
<td>Sample B</td>
<td>MSESD</td>
<td>1135 ± 1.3</td>
<td>0.059</td>
<td>-49.2 ± 0.7</td>
<td>1.5 (1.6; 1.4)</td>
<td>62.0 (63.0; 61.0)</td>
</tr>
<tr>
<td>Sample C</td>
<td>PPT</td>
<td>1558 ± 2.7</td>
<td>0.356</td>
<td>-55.1 ± 0.9</td>
<td>1.4 (1.4; 1.4)</td>
<td>14.5 (14.2; 14.8)</td>
</tr>
</tbody>
</table>


